Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancer.
2/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
10 patients (47.
I · Intervention 중재 / 시술
nanoparticle-formulated AZD2811 500 mg IV (Day 1; 21-day cycles) with granulocyte colony-stimulating factor (Day 8)
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[METHODS] Eligible patients received nanoparticle-formulated AZD2811 500 mg IV (Day 1; 21-day cycles) with granulocyte colony-stimulating factor (Day 8).
OpenAlex 토픽 ·
Lung Cancer Research Studies
Microtubule and mitosis dynamics
Protein Degradation and Inhibitors
[BACKGROUND] Aurora kinase B (AURKB) is overexpressed in lung cancer and is associated with poor prognosis.
APA
Melissa L. Johnson, Giulia Fabbri, et al. (2026). Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancer.. British journal of cancer. https://doi.org/10.1038/s41416-026-03414-0
MLA
Melissa L. Johnson, et al.. "Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancer.." British journal of cancer, 2026.
PMID
41933194 ↗
Abstract 한글 요약
[BACKGROUND] Aurora kinase B (AURKB) is overexpressed in lung cancer and is associated with poor prognosis. AZD2811 is an AURKB inhibitor that demonstrated tolerability during a Phase I dose-escalation study in patients with advanced solid tumours, including small-cell lung cancer (SCLC). Here we report the dose-expansion results.
[METHODS] Eligible patients received nanoparticle-formulated AZD2811 500 mg IV (Day 1; 21-day cycles) with granulocyte colony-stimulating factor (Day 8). Dose-expansion endpoints included: preliminary antitumour activity, safety/tolerability, pharmacokinetics, and biomarker-based disease monitoring.
[RESULTS] One of 21 enrolled patients achieved a partial response for an objective response rate of 4.8%; stable disease ≥6 weeks was observed in 10 patients (47.6%). The most common AZD2811-related AEs were decreased neutrophil and white blood cell count, anaemia, and decreased platelet count; grade ≥3 AZD2811-related AEs occurred in 15/21 patients. Baseline ctDNA levels were prognostic, and on-treatment ctDNA changes mirrored clinical response and identified progression early, suggesting it could be an effective surrogate for tumour tissue. Molecular profiling of paired tumour biopsies demonstrated AZD2811 pharmacodynamic activity and identified genes/pathways potentially linked to response.
[CONCLUSION] A personalised surveillance strategy may provide a novel avenue to monitor SCLC, supporting further investigation and potential broader clinical application.
[CLINICAL TRIAL REGISTRATION] NCT02579226.
[METHODS] Eligible patients received nanoparticle-formulated AZD2811 500 mg IV (Day 1; 21-day cycles) with granulocyte colony-stimulating factor (Day 8). Dose-expansion endpoints included: preliminary antitumour activity, safety/tolerability, pharmacokinetics, and biomarker-based disease monitoring.
[RESULTS] One of 21 enrolled patients achieved a partial response for an objective response rate of 4.8%; stable disease ≥6 weeks was observed in 10 patients (47.6%). The most common AZD2811-related AEs were decreased neutrophil and white blood cell count, anaemia, and decreased platelet count; grade ≥3 AZD2811-related AEs occurred in 15/21 patients. Baseline ctDNA levels were prognostic, and on-treatment ctDNA changes mirrored clinical response and identified progression early, suggesting it could be an effective surrogate for tumour tissue. Molecular profiling of paired tumour biopsies demonstrated AZD2811 pharmacodynamic activity and identified genes/pathways potentially linked to response.
[CONCLUSION] A personalised surveillance strategy may provide a novel avenue to monitor SCLC, supporting further investigation and potential broader clinical application.
[CLINICAL TRIAL REGISTRATION] NCT02579226.
같은 제1저자의 인용 많은 논문 (3)
- Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial.
- A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer.
- Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer.